Breast Cancer Care comment on claims that long-term use of Tamoxifen may increase proportion of oestrogen receptor (ER) negative cancers which develop in the opposite breast

Comment on research published in Cancer Research which claims that long-term use of Tamoxifen may increase the proportion of oestrogen receptor (ER) negative cancers which develop in the opposite breast.

Dr Emma Pennery, Clinical Director at Breast Cancer Care, said:

“Patients should be reassured that Tamoxifen remains very effective in reducing the overall risk of recurrences and deaths from breast cancer, as the authors state.

“The study shows that long-term use of Tamoxifen does not increase incidence of breast cancer in the opposite breast, but it may increase the proportion of oestrogen receptor negative cancers. However, it is important to remember that many women will never develop breast cancer in the other side.

“Anyone with concerns should speak to their healthcare professional or call Breast Cancer Care’s freephone helpline, 0808 800 6000.”

ENDS

For further media information, please contact
Laura Grossart
0207 960 3473/07702 901 334
laura.grossart@breastcancercare.org.uk

Breast Cancer Care is here for anyone affected by breast cancer. We bring people together, provide information and support, and campaign for improved standards of care. We use our understanding of people’s experience of breast cancer and our clinical expertise in everything we do. Visit www.breastcancercare.org.uk or call our free helpline on 0808 800 6000.